UGT1A1 Irinotecan toxicity

Alphabetical Test listing

UGT1A1 Irinotecan toxicity-994

UGT1A1 Irinotecan toxicity

Irinotecan (Camptosar®) is used, or under evaluation, in a broad spectrum of solid tumors, and is often prescribed for treating patients with metastatic cancer of the colon or rectum, especially when 5-fluorouracil treatment has not been entirely successful. Severe toxicity (eg, grade 4 neutropenia) is commonly observed in cancer patients receiving irinotecan who carry the UGT1A1*28 allele, also called TA. This test result will provide valuable information to physicians prior to initiating or modifying treatment or supplementing treatment with additional drugs. UGT1A1 variants have also been reported in patients with disorders of bilirubin metabolism, such as Crigler-Najjar Types I and II, as well as Gilbert syndrome. Between 80% to 100% of Caucasian patients with Gilbert syndrome are reported to have either one or two copies of UGT1A1*28. G71R (*6), a UGT1A1 variant reported in Asian patients with Gilbert syndrome, is not detected by this assay.

EDTA whole blood
5.0 mL
3.0 mL

Lavender (EDTA), 10mL


ACD whole blood

Yellow ACD (A or B)




Yellow ACD (A or B)


Ambient (preferred) - 7 days

Refrigerated - 1 month

Frozen - 2 years

  • Hemolysis
  • Quantity not sufficient for analysis
  • Improper container/anticoagulant
LabCorp RTP (511200): R-NX
Weekly/as needed
6 - 9 days

Polymerase chain reaction (PCR) and capillary electrophoresis


An interpretive report will be provided

Result 41044-9